Filter
1688
Filtered Results: 1688
Text search:
drug
formulations
Featured
Recommendations
184
New Publications
556
Language
Document type
No document type
1065
Guidelines
285
Studies & Reports
181
Manuals
63
Strategic & Response Plan
40
Training Material
20
Fact sheets
20
Situation Updates
6
Infographics
4
Resource Platforms
2
App
1
Online Courses
1
Countries / Regions
India
102
Kenya
71
Uganda
53
Tanzania
42
Global
39
Malawi
37
Nepal
36
Ethiopia
36
South Africa
34
Liberia
33
Sierra Leone
29
Nigeria
28
Ghana
27
Zambia
27
Rwanda
26
Bangladesh
23
Philippines
22
Namibia
22
Zimbabwe
21
Myanmar / Burma
21
Latin America and the Carribbean
19
Western and Central Europe
19
Cambodia
17
Africa
16
Botswana
12
Lesotho
11
Senegal
11
Indonesia
10
Eswatini/ Swaziland
10
South–East Asia Region
9
Cameroon
8
Haiti
7
Congo, Democratic Republic of
7
Burkina Faso
6
Eastern Europe
6
Ukraine
5
Syria
5
Russia
5
Benin
4
Albania
4
Asia
4
Pakistan
4
Tajikistan
3
Thailand
3
Mozambique
3
Eastern Europe and Central Asia
3
Georgia
3
South Sudan
3
Madagascar
3
North Macedonia
2
Iran
2
Afghanistan
2
Guinea
2
USA
2
Middle East and North Africa
2
Western Pacific Region
2
Gabon
2
United Kingdom
2
East and Southern Africa
2
Southern Africa
2
Côte d’Ivoire / Ivory Coast
2
Argentina
2
Lebanon
2
Vietnam
2
Sri Lanka
2
Sudan
2
Libya
2
Colombia
1
Timor Leste/ East Timor
1
Australia
1
Gambia
1
Kazakhstan
1
Chile
1
Laos
1
Kyrgyzstan
1
Congo-Brazzaville
1
Niger
1
Peru
1
Malaysia
1
Morocco
1
Venezuela
1
Jordan
1
Ireland
1
Saudi Arabia
1
Paraguay
1
North America
1
Turkmenistan
1
Denmark
1
France
1
Tunisia
1
Bolivia
1
Papua New Guinea
1
Brazil
1
Moldova
1
Yemen
1
Greece
1
Mali
1
Bhutan
1
Iraq
1
Authors & Publishers
Publication Years
Category
Countries
746
Clinical Guidelines
249
Women & Child Health
77
Public Health
76
Key Resources
31
Capacity Building
25
Pharmacy & Technologies
25
Toolboxes
HIV
178
TB
167
Pharmacy
111
AMR
104
Mental Health
89
COVID-19
49
NTDs
37
NCDs
28
Rapid Response
26
Caregiver
26
Ebola
21
Refugee
16
Planetary Health
12
Disability
11
Global Health Education
8
Specific Hazards
6
Health Financing Toolbox
6
Conflict
6
Natural Hazards
5
Cholera
5
Polio
4
Social Ethics
3
Zika
3
Front. Public Health, 30 April 2021 | https://doi.org/10.3389/fpubh.2021.628744
The PHC STGs and EML should be used by healthcare workers providing care at clinics, community health centres, and gateway clinics at hospitals.
Pharmaceutical and Therapeutics Committees (PTCs) are responsible for ensuring the availability of medicines listed in the PHC EML at those facilities, as...
2nd edition. These guidelines include several notable changes from the first edition. For cutaneous leishmaniasis, ketoconazole has been removed from the list of treatment options; the number of Leishmania species for which there is strong evidence for the efficacy of miltefosine has increased from ...
Recommendations on the initiation and continuing use of nine common types of contraceptive methods are covered by the tool. In addition to looking at individual medical conditions or characteristics, users may also easily combine multiple conditions or characteristics and view the guidance on each c...
The WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) was launched in 2015 to foster AMR surveillance and inform strategies to contain AMR. The system started with surveillance of AMR in bacteria causing common human infections and has expanded its scope to include surveillance...
Although Shiga toxin-producing Escherichia coli (STEC) have been isolated from a variety of food production animals, they are most commonly associated with ruminants from which we derive meat and milk. Because of the widespread and diverse nature of ruminant-derived food production, coupled with the...
This publication represents a key step forward in translating Control of the leishmaniases (WHO Technical Report Series, No. 949) into a more practical tool for health personnel directly involved in the case management of cutaneous leishmaniasis. With this manual, countries will have, for the first ...
The World Health Organization (WHO) and the global community of countries, partners, donors, technical experts, scientists and field implementation teams continue to work towards the ultimate goal of a world free of the burden of neglected tropical diseases (NTDs).
This guideline for the prevention and control of chikungunya fever
(CF) is intended for use by all peripheral health workers in the Region and
is based on the strategy outlined above. This document will focus mainly
on preventing, predicting and detecting outbreaks, and after detection,
investig...
Despite a historical association with poor tolerability, a comprehensive review on safety of antileishmanial chemotherapies is lacking. We carried out an update of a previous systematic review of all published clinical trials in visceral leishmaniasis (VL) from 1980 to 2019 to document any reported ...
Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
recommended
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys...
The availability of controlled medicines is crucial for patients requiring palliative care, pain relief and symptom management. Many individuals worldwide, especially in low- and middle-income countries, continue to experience limited access to these essential medicines. Enhancing access to controll...
Due to high routine vaccination coverage, overall counts of diphtheria case have significantly declined in the Western Pacific Region recently. However, diphtheria is still prevalent in several countries and areas of the Region and remains a public health issue due to its high case fatality rate.
...
This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document:
Broad spectrum Pan-African polyvalent antivenoms: products ...
This document lays out economic arguments for investing in the Access to COVID-19 Tools Accelerator (ACT-Accelerator). Framed within an overall context that recognizes the broader human health and societal impacts of the COVID-19 crisis, ACT-Accelerator's Economic Investment Case argues that investm...
Disability inclusive shelter programming enables persons with disabilities to contribute more to their communities, participate more in consultations and decision-making, and facilitate their own protection. The key concepts include: Disability inclusive shelter programming is both a process and an ...
For the global community to be able to achieve ambitious targets relating to the prevention and treatment of HIV, viral hepatitis and sexually transmitted infections (STIs), multiple types of medicines must be widely accessible to all affected populations in all countries.
The purpose of this rep...
Hepatitis B (HBV) infection is a major public health problem and cause of chronic liver disease.
The 2024 HBV guidelines provide updated evidence-informed recommendations on key priority topics. These include expanded and simplified treatment criteria for adults but now also for adolescents; expa...
Diabetes is a significant public health issue that affects approximately one in 10 adults globally, with type 2 diabetes accounting for 90–95% of cases. This chronic condition causes considerable morbidity and mortality and is growing in impact, with cases projected to rise from 537 million in 202...
The document provides detailed clinical guidelines for the therapy of Type 1 Diabetes as developed by the German Diabetes Association (DDG). It focuses on individualized insulin therapy, structured patient training, and monitoring of blood glucose levels. The guidelines emphasize preventing complica...
